Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
International Journal of Hematology|February 11, 2022
Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in JapanTakayuki Ikezoe, Hideyoshi Noji, Yasutaka Ueda, et al.
Medicine|May 1, 2004
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and JapanJun-Ichi Nishimura, Yuzuru Kanakura, Russell E Ware, et al.
Blood Advances|January 4, 2018
Use of the complement inhibitor Coversin to treat HSCT-associated TMATimothy H J Goodship, Fernando Pinto, Wynn H Weston-Davies, et al.
British Journal of Haematology|September 1, 2023
A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in JapanKen Ishiyama, Yuji Yonemura, Tatsuya Kawaguchi, et al.
International Journal of Hematology|January 12, 2011
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trialYuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, et al.
Annals of Hematology|July 18, 2025
Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview surveyYasutaka Ueda, Naoshi Obara, Shikiko Ueno, et al.
The Lancet. Haematology|November 29, 2023
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trialJong Wook Lee, Morag Griffin, Jin Seok Kim, et al.
Blood|December 19, 2024
Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVHAustin Kulasekararaj, Morag Griffin, Caroline Piatek, et al.
International Journal of Hematology|September 2, 2020
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patientsKen Ishiyama, Shinji Nakao, Kensuke Usuki, et al.
Hemasphere|July 15, 2026
Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safetyMorag Griffin, Bruno Fattizzo, Jong Wook Lee, et al.
Pageof 8